68 results
Objectives:Primary:• To assess progression free survival (PFS) when treated with lanreotide Autogel® 120 mg administered every 14 days based on Response Evaluation Criteria in Solid Tumours (RECIST) v1.0, and according to central review.Secondary:•…
The aim of this study is to explore the added value of the indol profile in comparison to serotonin in platelets and 5-HIAA in urine for diagnosis and potentially management of neuroendocrine tumors including gastrinomas, pNETs and brochopulmonary…
The purpose of the study is to investigate how quickly and to what extent BIM23B065 is distributed, metabolized (broken down) and excreted from the body, and what the main route of excretion from the body is (urine or feces); this is called…
Firstly, to study the reduction in sick-leave time achieved by the treatment protocol. Secondly to study the quality of life in the patients treated in the fast-track protocol, to study the reduction in societal costs and to stdy the efficacy of a…
Primary objectives:* To evaluate efficacy of adjuvant 166Ho-radioembolization (166Ho-RE) after systemic 177Lu-dotatate in a non-comparative phase II study Secondary objectives:* To establish the safety and toxicity profile of adjuvant 166Ho-RE after…
The aim of this study is to investigate if the NETest is useful in the follow up program after curative resection in patients with pNET. Therefore the diagnostic accuracy of the NETest in resected patients with pNET will be analysed. The study is…
1.To monitor the safety and tolerability of racecadotril in combination with 111In-DOTA-MG112.To study in patients whether the neutral endopeptidase (NEP) inhibitor racecadotril improves the in vivo stability of the radiopeptide 111In-DOTA-MG11
The study aims to determine the value of combined 124I PET and FDG PET to avoid futile treatment with 131I. Secundary aims are to validate functional imaging with histopathological correlation, and to optimize and standardize the new 124I technique…
To investigate the additional value of MRI and MRI-guided biopsy in men with an elevated PSA in the general practitioners* (GP) practice regarding the detection of both insignificant and significant cancer, and reduced biopsies.
To assess the treatment effect of BEZ235 relative to everolimus on progression free survival in patients with advanced pancreatic neuroendocrine tumors who have not been previously treated with an mTOR inhibitor.
The purpose of this study is to evaluate the effect of PRRT with 177Lu-octreotate on circulating NET transcriptomes. In particular, the variation of circulating NEN transcripts will be correlated to the response to PRRT to test whether this analysis…
To evaluate the efficacy of pasireotide LAR and everolimus alone or in combination in progressive patients with a well differentiated neuroendocrine tumor of the lung or thymus.
The primary objective of the Phase 2 part of the study is to determine if overall survival(OS) in patients with Stage II-IV unresectable pancreatic cancer administered LY2603618 and gemcitabine combination therapy exceeds gemcitabine monotherapy OS.…
Primary objective: To determine the efficacy of RAD001 in patients with progressive irresectable recurrent or metastatic differentiated thyroid carcinoma Secondary objectives:-To determine maximum percentage of tumor reduction-To describe activity…
To evaluate PFS with XL184 treatment as compared with placebo in subjects with unresectable, locally advanced, or metastatic MTC to see if the investigational drug XL184 is effective in delaying the growth of the tumor.
Evaluating the efficacy and safety of sunitinib in patients with progressive, advanced/metastatic well-differentiated, unresectable pancreatic neuroendocrine tumors.
To determine whether treatment with BEZ235 plus best supportive care prolongs PFS compared with placebo plus best supportive care in patients with advanced pancreas NET, after failure of a mTOR inhibitor therapy
The primary objective of this study is to assess the objective response rates (ORR) for two starting doses of vandetanib, 150 mg and 300 mg in patients with unresectable locally advanced or metastatic MTC having progressive or symptomatic disease.…
To determine whether treatment with everolimus 10 mg daily plus best supportive care prolongs PFS compared with placebo plus best supportive care in patients with advanced NET of GI or lung origin without a history of carcinoid symptoms
To investigate if sunitinib has clinical significant activity in patients with metastatic/recurrent paraganglioma/pheochromocytoma.